

1 **PCSK9 inhibition in myeloid cells enhances cardioprotection**  
2 **beyond its LDL cholesterol-lowering effects**

3

4 Shin Hye Moon, BSc<sup>\*</sup>; Hyo Won Ki, MSc<sup>\*</sup>; Na Hyeon Yoon, MSc; Katherine I. Chung, BSc; Huiju Jo,  
5 MSc; Jing Jin, PhD; Sejin Jeon, PhD; Seong-Keun Sonn, PhD; Seungwoon Seo, PhD; Joowon Suh,  
6 PhD; Hyeon Yon Kweon, PhD; Yun Seo Noh, BSc; Won Kee Yoon, PhD; Seung-Jun Lee, MD, PhD;  
7 Chan Joo Lee, MD, PhD; Nabil G. Seidah, PhD; Sung Ho Park, PhD; Goo Taeg Oh, DVM, PhD

8

9 <sup>\*</sup> Correspondence to: Goo Taeg Oh, DVM, PhD, Heart-Immune-Brain Network Research Center,  
10 National Creative Initiatives, Department of Life Sciences, Ewha Womans University, Seoul, 03760,  
11 Republic of Korea; [gootaeg@ewha.ac.kr](mailto:gootaeg@ewha.ac.kr); or Sung Ho Park, PhD, Department of Biological Sciences,  
12 Ulsan National Institute of Science & Technology (UNIST), Ulsan, 44919, South Korea;  
13 [parksu@unist.ac.kr](mailto:parksu@unist.ac.kr)

14 <sup>\*</sup>Shin Hye Moon, Hyo Won Ki contributed equally.

15

1 **BACKGROUND:** Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9),  
2 which regulates plasma cholesterol content by degrading LDL receptor, are correlated with the risk of  
3 acute myocardial infarction (AMI). Recent studies suggested that PCSK9 improves cardiac function  
4 beyond its effects on LDL cholesterol levels after cardiac ischemic injury, but its precise mechanism  
5 remains unclear.

6 **METHODS:** We examined the interrelationship and functional significance of PCSK9 and cardiac  
7 myeloid cells in ischemic hearts from AMI-induced *Pcsk9*<sup>-/-</sup> and *Lyz2*<sup>cre</sup>*Pcsk9*<sup>fl/fl</sup> mice, as well as in  
8 serum samples from coronary artery disease (CAD) patients treated with PCSK9 antibodies (Ab).  
9 Single-cell RNA sequencing (scRNA-seq) was conducted to identify heterogenous cardiac  
10 macrophage clusters and to investigate the impact of adaptive remodeling due to PCSK9 deficiency  
11 during AMI. Additionally, the regulatory effect of the myeloid-PCSK9/VEGF-C pathway was  
12 assessed *in vitro* as a potential therapeutic strategy.

13 **RESULTS:** Our study demonstrated that PCSK9 deficiency induces diverse changes in myeloid  
14 cells and macrophages, potentially offering cardiac protection following AMI, irrespective of LDL  
15 cholesterol homeostasis. The scRNA-seq identified a subset of PCSK9-dependent cardiac  
16 macrophages (PDCMs) enriched in activator protein-1 (AP-1)-related pathways, functioning as  
17 reparative macrophages. These PDCMs were shown to enhance vascular endothelial growth factor C  
18 (VEGF-C) secretion and activate Akt signaling in cardiac endothelial cells, leading to improved  
19 cardiac remodeling. Notably, CAD patients treated with PCSK9 inhibitors exhibited increased  
20 numbers of myeloid cells with PDCM-like features, including elevated VEGF-C levels, consistent  
21 with our findings in mice.

22 **COUNCLUSIONS:** Targeting PCSK9 in myeloid cells could offer cardioprotective effects by  
23 increasing AP-1 activity and VEGF-C expression of PDCMs, presenting a novel approach to  
24 preventing cardiac dysfunction in AMI. This strategy could expand the clinical use of existing PCSK9  
25 inhibitors beyond just lowering LDL cholesterol.

26

27 **Key Words:** coronary artery disease, lipid homeostasis, PCSK9 inhibitors, cardiac macrophages,  
28 activator protein-1, vascular endothelial growth factor C

29

## 1 **Clinical Perspective**

### 2 **What is New?**

- 3 ■ Myeloid-PCSK9 deficiency attenuated cardiac dysfunction post-acute myocardial infarction (AMI)  
4 without affecting plasma lipid levels. These findings position PCSK9 as a novel immune regulator  
5 of macrophages, revealing functions independent of its role in LDL cholesterol regulation.
- 6 ■ We demonstrated PCSK9-dependent cardiac macrophages (PDCMs) that play a reparative role  
7 under ischemic conditions influenced by PCSK9, using single-cell RNA sequencing (scRNA-seq)  
8 of CD45<sup>+</sup> leukocytes following AMI.
- 9 ■ Strong enrichment of AP-1 family proteins in PDCMs led to reparative VEGF-C signaling in  
10 endothelial cells and improved cardiac remodeling, independent of PCSK9's conventional role in  
11 cholesterol homeostasis.
- 12 ■ In coronary artery disease (CAD) patients, PCSK9 inhibition augmented myeloid cell populations  
13 towards a reparative phenotype and elevated VEGF-C levels, aligning with our findings in mice.

### 14 **What Are the Clinical Implications?**

- 15 ■ Myeloid-derived PCSK9 is pathobiologically significant, directly influencing immune functions  
16 and contributing to cardiac remodeling after AMI, suggesting that targeting myeloid-specific  
17 PCSK9 could be a valuable therapeutic approach.
- 18 ■ Given that the reparative effects of PCSK9 inhibitors on macrophages are preserved in CAD  
19 patients, this strategy could broaden the clinical applications of existing PCSK9 inhibitors beyond  
20 LDL cholesterol regulation.

21

### 22 **Nonstandard Abbreviation and Acronyms**

<b>AMI</b>	acute myocardial infarction
<b>CAD</b>	coronary artery disease
<b>PCSK9</b>	pro-protein convertase subtilisin/kexin type 9
<b>LDL</b>	low-density lipoprotein
<b>PDCM</b>	PCSK9-dependent cardiac macrophages
<b>MCECs</b>	mouse cardiac endothelial cells
<b>HCMEC</b>	human cardiac microvascular endothelial cells

## 1 **Introduction**

2 Acute myocardial infarction (AMI) is a leading global cause of mortality, and it is characterized by a  
3 pronounced inflammatory response in the heart and blood. This response exacerbates cell death,  
4 impairs heart function, and promotes ventricular adverse remodeling.<sup>1</sup> Despite available therapeutic  
5 targets, AMI carries high risks of heart failure<sup>2</sup> and mortality, emphasizing the need for further  
6 research into immune cell mechanisms to improve treatment strategies.

7 Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily known to increase circulating  
8 LDL cholesterol (LDL-c) levels by promoting LDL receptor (LDLR) degradation.<sup>3-5</sup> However,  
9 previous studies revealed that PCSK9 inhibition and deletion significantly reduce cardiac dysfunction<sup>6</sup>,  
10 suggesting a potential role of immune cells in the reparative phase within the ischemic heart.<sup>7</sup>  
11 Macrophages are highly active cell types throughout all stages after AMI, including the inflammatory,  
12 tissue repair, and cardioprotective phases.<sup>8,9</sup> Therefore, understanding the influence of PCSK9 on  
13 macrophages is essential for diagnosing and treating cardiovascular diseases, including myocardial  
14 infarction and atherosclerosis.

15 In this study, we revealed that PCSK9 deletion induces macrophage heterogeneity with reparative  
16 characteristics against AMI, defining them as PCSK9-dependent cardiac macrophages (PDCMs). We  
17 demonstrated that PDCMs are crucial in the reparative phase following myocardial infarction (MI),  
18 promoting cardiac healing and reducing adverse remodeling. Mechanistically, activated activator  
19 protein-1 (AP-1) in PDCMs induces the production of vascular endothelial cell growth factor C  
20 (VEGF-C) to activate Akt signaling in endothelial cells and facilitate cardiac repair and regeneration.  
21 Furthermore, we observed that PCSK9 antibody-treated patients with coronary artery disease (CAD)  
22 have PDCM-like features in blood myeloid cells. Collectively, we verified that targeting PCSK9 in  
23 myeloid cells (myeloid-PCSK9) enhances reparative tissue remodeling through the AP-1/VEGF-C/p-  
24 Akt axis, promoting protective effects from PDCMs to endothelial cells in ischemic hearts,  
25 irrespective of LDL-c levels.

26

## 1 **Methods**

2 Data, analytical methods, and study materials that support the findings of this study are available from  
3 the corresponding author on reasonable request. Detailed methods are described in the Data  
4 Supplement.

5

## 6 **Mice Study Approval**

7 All animal experiments were approved by the Institution Animal Care and Use Committees (IACUC)  
8 of Ewha Womans University, Seoul, Korea (IACUC No. 19-004, and 21-051).

9

## 10 **Human Samples**

11 The Institutional Review Board of Severance Hospital (Seoul, Korea; IRB: 4-2023-0509) approved  
12 the protocol for collecting human blood samples. Written informed consent was provided by all  
13 participants before enrollment. Identifying information was removed from all samples before analysis  
14 for strict privacy protection. All experiments conducted with human blood samples were performed in  
15 accordance with the relevant guidelines and regulations.

16

## 17 **Data availability**

18 scRNA-seq data for this project have been deposited at NCBI's Gene Expression Omnibus (GEO) and  
19 GSE number is pending.

20

## 21 **Statistical Analysis**

22 All statistical analyses were conducted using GraphPad Prism 8 (GraphPad). Comparisons between  
23 two groups were performed using a paired or unpaired two-tailed Student's *t*-test or nonparametric  
24 two-tailed Mann–Whitney U-test, whereas comparisons among three or more groups were performed  
25 using one-way ANOVA. Data were normalized to the control group to reduce batch effects in some  
26 experiments. Mouse survival was measured by the number of deaths after LAD ligation, and the data  
27 was analyzed using the Kaplan–Meier method. The results were presented as the means  $\pm$  SEM, and *P*  
28  $< 0.05$  was considered statistically significant.

29

## 1 Results

### 2 Myeloid-PCSK9 deficiency inhibits myocardial damage without affecting lipid 3 homeostasis

4 Previous studies suggested that PCSK9 exacerbates cardiac dysfunction post-AMI<sup>6,10</sup>, with high  
5 circulating PCSK9 levels associated with an increased CAD risk.<sup>11-14</sup> Although PCSK9 is primarily  
6 secreted by hepatocytes, it is also expressed by cardiac macrophages, endothelial cells, and smooth  
7 muscle cells.<sup>15</sup> Thus, PCSK9 inhibition has been demonstrated to reduce CAD risk by affecting  
8 immune cell populations. Several reports found that PCSK9 blockade attenuates cardiovascular  
9 diseases such as atherosclerosis<sup>16,17</sup> and aortic aneurysm.<sup>18</sup> However, there is a lack of cell-specific  
10 studies on PCSK9 in myocardial infarction, particularly regarding the relationship between immune  
11 cells and PCSK9. To elucidate the role of PCSK9 in immune cells during heart injury, we subjected  
12 conventional PCSK9-deficient (*Pcsk9*<sup>-/-</sup>) and myeloid cell-specific PCSK9 knockout (*Lyz2*<sup>cre</sup>*Pcsk9*<sup>fl/fl</sup>)  
13 mice to left anterior descending (LAD) coronary artery ligation or sham surgery. Cardiac function and  
14 immune cell populations were assessed by echocardiography and flow cytometry, respectively, on  
15 days 3 and 7 post-AMI (Figure 1A and Figure IA in the Data Supplement). As expected, PCSK9  
16 deficiency reduced plasma cholesterol levels and significantly improved mortality rates, although  
17 there was no significant change in the heart weight to body weight (HW/BW) ratio (Table I and  
18 Figure IB-ID in the Data Supplement). After MI, PCSK9 deficiency also reduced infarct size,  
19 attenuated wall thinning, and improved cardiac contractile function, indicating a protective effect  
20 (Figure IE, IF and Table II in the Data Supplement). These findings were associated with decreased  
21 numbers of total leukocytes and macrophages in the PCSK9-deficient infarcted heart, but no  
22 differences in the counts of other immune cells were recorded (Figure IG and IH in the Data  
23 Supplement).

24 Assessment of the response of macrophages to AMI indicated that PCSK9 plays a pivotal role in  
25 macrophages during cardiac ischemia. Substantiating this finding, we confirmed that *Pcsk9* mRNA  
26 levels were considerably reduced in CD11b<sup>+</sup> myeloid cells isolated from the sham-operated or post-  
27 AMI hearts of *Lyz2*<sup>cre</sup>*Pcsk9*<sup>fl/fl</sup> mice (Figure IIA in the Data Supplement). Interestingly, myeloid cell-  
28 specific PCSK9 deficiency improved the survival rate and reduced the incidence of cardiac rupture  
29 post-AMI without affecting the HW/BW ratio (Figure 1B, Figure IIB and IIC in the Data Supplement).  
30 Masson's trichrome staining and echocardiography illustrated that myeloid-PCSK9 deletion reduced  
31 infarct size, maintained left ventricular (LV) wall thickness, and improved cardiac function, as  
32 evidenced by enhanced EF and reduced LV end-systolic volume, LV end-diastolic volume, and LV  
33 end-diastolic diameter (Figure 1C and 1D, Figure IID and IIE, and Table III in the Data Supplement).  
34 Additionally, flow cytometry revealed that myeloid-PCSK9 deficiency reduced cardiac macrophage

1 counts, whereas the counts of other immune cells were not changed after AMI (Figure 1E and Figure  
2 IIF in the Data Supplement). These results revealed that targeting myeloid-PCSK9 attenuates cardiac  
3 injury and improves survival following AMI.

4 PCSK9 influences plasma cholesterol homeostasis by increasing LDL-c levels through clearing  
5 LDLR.<sup>19,20</sup> Additionally, macrophages play a significant role in reverse cholesterol transport and the  
6 development of cardiovascular diseases.<sup>21,22</sup> To investigate the association between PCSK9 and  
7 macrophages in plasma cholesterol homeostasis, we evaluated lipoprotein uptake and plasma lipid  
8 levels. Flow cytometry using the fluorescence probe BODIPY (493/503) demonstrated that neither  
9 sham surgery or cardiac ischemia affected the lipid droplet accumulation of F4/80<sup>+</sup> macrophages in  
10 *Pcsk9*<sup>-/-</sup> and *Lyz2*<sup>cre</sup>*Pcsk9*<sup>fl/fl</sup> mice compared with their controls (*Pcsk9*<sup>+/+</sup> and *Pcsk9*<sup>fl/fl</sup>, respectively,  
11 Figure 1F). Plasma lipid profiles, including total cholesterol (CHO), HDL cholesterol (HDL-c), and  
12 LDL-c levels, were not altered in mice with myeloid-specific PCSK9 deficiency (Table 1). These data  
13 imply that myeloid-PCSK9 deficiency does not impact plasma cholesterol homeostasis. Overall, our  
14 findings indicate that myeloid-PCSK9 exacerbates myocardial injury in the ischemic state  
15 independent of its effects on LDL-c levels.

## 16 **PCSK9 alters cardiac macrophage heterogeneity after AMI**

17 Single-cell RNA sequencing (scRNA-seq) was conducted to identify changes in macrophage  
18 heterogeneity and understand the effects of PCSK9 deficiency on cardiac repair. Analysis of sorted  
19 CD45<sup>+</sup> cells from noninfarcted and infarcted hearts revealed eight transcriptionally distinct immune  
20 cell populations by representative markers (Figure IIIA-III C in the Data Supplement). Ischemic  
21 damage led to significant increases in monocyte/macrophage (Mo/Mac) and neutrophil counts,  
22 whereas those of B cells, T cells, and NK cells were decreased (Figure IIID and IIIE in the Data  
23 Supplement). These data indicate that cardiac ischemia dramatically alters immune cell heterogeneity,  
24 with a significant involvement of macrophages, as expected.

25 To further characterize the role of macrophage-specific PCSK9 deficiency in cardiac regeneration,  
26 we defined subpopulations of Mo/Mac and Mo/Mac/DC clusters through clustering analysis. Eleven  
27 clusters were identified, including five macrophage clusters, three monocyte clusters, and two DC  
28 clusters (Figure 2A and Figure IVA in the Data Supplement). Notably, two macrophage clusters  
29 (Lyve1<sup>+</sup> and CX<sub>3</sub>CR1<sup>+</sup>MHCII<sup>+</sup>) were significantly restored in *Pcsk9*<sup>-/-</sup> hearts compared with the  
30 findings in *Pcsk9*<sup>+/+</sup> hearts on MI-D3 (Figure 2B, 2C and Figure IVB in the Data Supplement). Both  
31 clusters, which are known for their reparative roles, including angiogenic and wound healing  
32 characteristics, were previously identified in published studies.<sup>23-25</sup> To confirm the presence of  
33 reparative macrophages in the setting of PCSK9 deficiency, bone marrow-derived macrophages  
34 (BMDMs) from *Pcsk9*<sup>-/-</sup> mice were treated with IL-4 and IL-13 to generate PCSK9-deficient

1 BMDMs (BMDM(IL-4/IL-13)<sup>ΔPCSK9</sup>). The absence of PCSK9 increased the mRNA levels of anti-  
2 inflammatory genes (*Arg1*, *Mrc1*, *Tgf-β*) in BMDM(IL-4/IL-13)<sup>ΔPCSK9</sup> but not BMDM(IL-4/IL-13)<sup>Ctrl</sup>,  
3 whereas *Il-10* expression was not significantly affected (Figure IVC in the Data Supplement). These  
4 clusters, which we termed PDCMs, are believed to facilitate tissue remodeling and repair in AMI.  
5 Consistent with the results of scRNA-seq analysis, elevated expression of Lyve1 and CX<sub>3</sub>CR1 in  
6 F4/80<sup>+</sup> macrophages (PDCMs) was observed in the ischemic area of myeloid-specific PCSK9-  
7 deficient mice (Figure 2D-2G). Flow cytometry revealed increases in PDCM counts in the hearts of  
8 *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* mice compared with the findings in *Pcsk9<sup>fl/fl</sup>* mice on MI-D7 (Figure IVD in the Data  
9 Supplement). Together, these results suggest that PCSK9 alters macrophage heterogeneity in ischemia,  
10 and activated PDCMs, in the absence of PCSK9, may promote reparative processes at the site of  
11 cardiac ischemia.

## 12 **PDCMs drive cardiac regeneration**

13 Macrophages play central roles in cardiac healing and tissue remodeling post-MI, influencing other  
14 cell types such as endothelial cells, smooth muscle cells, and fibroblasts to orchestrate the  
15 regenerative process.<sup>8,26</sup> Our study explored the network of PDCMs with other cells in cardiac repair  
16 and regeneration. The data indicated that PDCMs exhibited advanced levels of cardiac muscle cell  
17 development, tissue development, and vasculogenesis compared with non-PDCMs based on scoring  
18 data (Figure 3A). During the regenerative phase of cardiac healing, myofibroblasts produce collagens,  
19 which help to maintain tissue structure and modulate the immunosuppressive functions of  
20 macrophages.<sup>27,28</sup> Immunofluorescence and Masson's trichrome staining demonstrated that PCSK9  
21 deficiency was associated with enhanced myofibroblast density ( $\alpha$ -smooth muscle actin) and collagen  
22 deposition in the injured heart, suggesting an improvement in wound healing capacity (Figure 3B and  
23 3C). PCSK9 deficiency in myeloid cells increased microvascular density (CD31) and elevated  
24 *Pecam1* mRNA expression, indicating an enhanced angiogenic response in the ischemic region  
25 (Figure 3D and 3E). Thus, PCSK9-deficient cardiac macrophages promote advanced levels of  
26 coalition with other cardiac cell types, thereby improving wound healing in the infarcted heart. These  
27 results indicate that PCSK9 plays a pivotal role in modulating macrophage-mediated cardiac repair  
28 and regeneration.

## 29 **PDCMs exhibit enrichment in AP-1, promoting cardiac recovery in the infarcted area**

30 PDCMs were identified as key regulators of the AMI repair process (Figure 2). To identify the critical  
31 regulators of PDCMs in the absence of PCSK9, Enrich R analysis was conducted. This analysis  
32 revealed elevated expression of AP-1 target genes in PDCMs following PCSK9 ablation (Figure 4A-  
33 4C). Immunoblotting of sorted CD45<sup>+</sup>Ly6G<sup>-</sup>CD11b<sup>+</sup> myeloid cells and F4/80<sup>+</sup> cardiac macrophages



1 from the hearts of mice with AMI verified the upregulation of Lyve1, CX<sub>3</sub>CR1, and AP-1 (c-Jun) in  
2 *Pcsk9*-deleted mice compared with the findings in controls (Figure 4D, Figure VA and VB in the Data  
3 Supplement). Collectively, these observations suggest that PCSK9 deficiency promotes AP-1  
4 activation in PDCMs, leading to enhanced healing signals and the inhibition of cardiac dysfunction.

### 5 **AP-1/VEGF-C axis in PDCMs stimulates reparative Akt signaling in endothelial cells**

6 AP-1 regulates macrophage activities, and it can promote the secretion of regenerative factors, such as  
7 VEGF.<sup>29</sup> To ascertain whether PCSK9 deletion facilitates the secretion of regenerative components in  
8 the infarcted heart, we quantified VEGF family expression post-MI. The mRNA levels of *Vegf-a* and  
9 *Vegfr3* did not differ in the ischemia area, whereas *Vegf-c* and *Vegfr2* mRNA levels were elevated  
10 (Figure 5A, 5B and Figure VIA, VIB in the Data Supplement). Additionally, immunoblotting  
11 indicated that VEGF-C expression was upregulated in both sorted F4/80<sup>+</sup> cardiac macrophages and  
12 CD11b<sup>+</sup> cardiac myeloid cells from myeloid-specific PCSK9 deficient ischemic hearts on MI-D7  
13 (Figure 5C and Figure VB in the Data Supplement). Although the assessment of improved VEGF-C  
14 activation and expression upon PCSK9 deficiency post-AMI suggest enhanced remodeling, these  
15 events could also reflect secondary effects related to the accentuation of restoration. To explore  
16 whether PCSK9 directly modulates VEGF-C synthesis by macrophages, we used BMDMs from  
17 *Pcsk9*-knockout mice. Secreted VEGF-C levels were higher in the BMDM(IL-4/IL-13)<sup>APCSK9</sup>  
18 supernatant under the AMI mimic conditions, as assessed by enzyme-linked immunosorbent assay  
19 (ELISA; Figure 5D).

20 VEGF-C secreted from PDCMs as induced by AP-1 could bind to endothelial cell receptors, thereby  
21 stimulating Akt reparative signaling pathways to improve angiogenic activities.<sup>30</sup> To determine  
22 whether VEGF-C stimulates Akt signaling pathways in endothelial cells during wound healing, we  
23 prepared and cultured mouse cardiac endothelial cells (MCECs) with VEGF-C and CoCl<sub>2</sub>. Using the  
24 scratch assay, we observed that VEGF-C enhanced MCEC migration under normal conditions after 12  
25 h (black vs. green) and under ischemic conditions after 24 h (blue vs. red; Figure 5E and 5F). In  
26 human cardiac microvascular endothelial cells (HCMECs), VEGF-C also increased wound healing in  
27 the scratch assay (black vs. green at 24 h). Even under ischemic conditions, VEGF-C significantly  
28 improved proliferation after 12 and 24 h (red vs. blue; Figure VIIA and VIIB in the Data Supplement).  
29 Additionally, to verify the activation of the damage repair system, we analyzed VEGF-C-related  
30 receptor expression and Akt activation in MCECs. VEGF-C improved VEGFR2 activation and  
31 expression and increased Akt activation under hypoxic conditions (red vs. blue; Figure 5G). These  
32 findings suggest that the VEGFR2/Akt axis in cardiac endothelial cells is activated by VEGF-C  
33 secreted from PDCMs, promoting cardiac damage restoration.

### 34 **Identification of PDCMs features in myeloid cells from patients with CAD and human**

## 1 **macrophages treated with a PCSK9 antibody**

2 To investigate the relationship between immune cell heterogeneity and circulating PCSK9 levels in  
3 patients with vascular disease, we assigned patients into three groups: i) patients with hypertension  
4 not taking statins (non-CAD; Control), ii) patients using only statin therapy after CAD diagnosis, and  
5 iii) patients using statins and a PCSK9 antibody for at least 2 months after a CAD diagnosis. ELISA  
6 confirmed the increase in the plasma PCSK9 concentration in both the statin-only therapy and PCSK9  
7 antibody treatment groups (Figure 6A). Flow cytometry revealed increases in myeloid cell and T cell  
8 counts among immune cell populations in patients treated with a PCSK9 antibody compared with the  
9 findings in patients treated with statins alone (Figure 6B, Figure VIIIA and VIIIB in the Data  
10 Supplement). The heterogeneity of myeloid cells, as observed *in vivo* and *in vitro*, was investigated in patients  
11 with CAD. Interestingly, we found that the myeloid cells from the PCSK9 antibody treatment group exhibited  
12 elevated expression of CX<sub>3</sub>CR1 and Lyve1 compared with the findings in the statin-only group, whereas CCR2  
13 expression did not differ between the groups (Figure VIIIC in the Data Supplement). These results imply  
14 that PCSK9 antibody administration induces heterogeneity in myeloid cells in the blood. Furthermore, the  
15 plasma VEGF-C concentration was significantly higher in the PCSK9 antibody treatment group than  
16 in the control and statin-only groups, whereas VEGF-A levels did not differ among the groups (Figure  
17 6C and Figure VIIID in the Data Supplement).

18 Moreover, to demonstrate whether blocking AP-1 in human macrophages reduces VEGF-C levels,  
19 THP-1(IL-4/IL-13) cells were treated with CoCl<sub>2</sub>, alirocumab (a PCSK9 inhibitor), and SR11302 (an  
20 AP-1 inhibitor). As expected, HIF-1 $\alpha$  expression increased under hypoxic conditions, LDLR  
21 expression improved following alirocumab administration<sup>5</sup>, and AP-1 (c-Jun) activation was blocked  
22 by SR11302 (Figure 6D and 6E). Notably, VEGF-C levels, which were reduced following AP-1  
23 blockade alone, were restored by joint PCSK9 and AP-1 blockade (Figure 6D and 6F). ELISA  
24 indicated that although alirocumab treatment alone did not affect VEGF-C secretion, SR11302  
25 reduced VEGF-C levels. Blocking both PCSK9 and AP-1 restored VEGF-C levels in the THP-1(IL-  
26 4/IL-13) cell supernatant (Figure 6G). Contrarily, the expression of VEGF-A, another regenerative  
27 factor, was not significantly affected by the inhibition of PCSK9 and AP-1 (Figure VIIIE in the Data  
28 Supplement). These findings indicate that AP-1 activation stimulates the secretion of VEGF-C,  
29 promoting cardiac protection and encouraging cardiac remodeling. The loss of PCSK9 in  
30 macrophages led to increased VEGF-C secretion, indicating that PCSK9 directly modulates VEGF-C  
31 synthesis by macrophages. Collectively, PCSK9-specific inhibition modulates myeloid cell  
32 phenotypes and elevates VEGF-C activation, which could represent a novel approach to enhancing  
33 cardiac remodeling and healing in MI and cardiovascular diseases.

34

## 1 **Discussion**

2 The critical aspects of AMI pathophysiology are compounded by the intricate cellular mechanisms  
3 involved in the initiation and resolution of early-stage inflammation, as well as longer-term effects  
4 related to cardiac remodeling. Cardiac macrophages have emerged as key regulators during all stages  
5 after AMI, and distinct heterogeneity influences cardiac remodeling during the inflammatory and  
6 reparative phases. In this study, we observed that macrophages display PCSK9-dependent  
7 heterogeneity as a component of cardiac remodeling post-AMI, linking PCSK9 to reparative  
8 macrophage activity through an immunological mechanism independent of its role in cholesterol  
9 regulation. The function of PCSK9 in macrophage activation is (patho)biologically important, as  
10 genetic or antibody-dependent modulation of PCSK9 activity resulted in improved wound healing and  
11 cardiac remodeling, which were associated with a shift in macrophage heterogeneity toward a  
12 reparative phenotype. These findings highlight a novel function for PCSK9 in regulating the balance  
13 of macrophage heterogeneity and open therapeutic avenues toward expanding the clinical application  
14 of PCSK9 inhibitors.

15 Myeloid macrophages play critical roles in regulating inflammatory response and maintaining tissue  
16 architecture.<sup>31</sup> We identified a novel subset of macrophages termed PDCMs, which facilitate healing  
17 and regeneration of infarcted tissue in mice lacking PCSK9 specifically in myeloid macrophages  
18 during the remodeling phase. Under hypoxic conditions, the phenotype of macrophages shifts from  
19 inflammatory to reparative earlier than observed under normoxic conditions, thereby initiating the  
20 repair process to promote myocardial recovery.<sup>32</sup> Previous studies illustrated that myeloid cell subsets  
21 exhibit regenerative functions following mild traumatic brain injury<sup>33</sup> and liver injury.<sup>31</sup> Therefore, in  
22 the context of an infarcted heart, PCSK9-dependent reparative macrophages likely play a crucial role  
23 in successful heart repair. Targeting PCSK9 in cardiac macrophages could offer promising therapeutic  
24 approaches to mitigate tissue damage after AMI.

25 PCSK9 regulates plasma LDL-c levels by promoting the lysosomal degradation of LDLR. Notably,  
26 our findings revealed that PCSK9 deficiency in cardiac myeloid cells attenuates AMI independently  
27 of LDL-c levels. The regulatory mechanism of PCSK9, beyond its role in cholesterol homeostasis,  
28 and its association with human diseases remain elusive. In hepatocytes, but not cardiac cells, cyclase-  
29 associated protein 1 (CAP1) has been identified as a key factor that binds to PCSK9 for caveolae-  
30 dependent endocytosis.<sup>4</sup> Inhibition of PCSK9–CAP1 binding has been found to suppress  
31 atherosclerotic inflammation independently of LDLR.<sup>34</sup> Other research demonstrated that PCSK9  
32 targets LDLR-related protein 5 (LRP5), which mediates lipid uptake in macrophages under  
33 atherosclerosis.<sup>16</sup> These findings suggest that proteins other than LDLR are also involved in PCSK9-  
34 related mechanisms in coronary arteries.

1 AP-1, well known for its role in wound healing in skin fibroblasts<sup>35</sup>, does not have a well-defined  
2 role in cardiac macrophages concerning ventricular remodeling post-MI. Cardiovascular  
3 pathophysiology increases cardiac workload as a compensatory mechanism, potentially increasing the  
4 risk of heart failure.<sup>36</sup> Under stress, the AP-1 component JunD has been demonstrated to reduce  
5 hypertrophy.<sup>37,38</sup> Conversely, *in vivo* studies revealed that hearts lacking Jun develop fibrosis and  
6 exhibit increased myocyte apoptosis, potentially leading to dilated cardiomyopathy.<sup>39</sup> These findings  
7 suggest that Jun is essential for initiating a transcriptional program that adapts to increased workload  
8 in the heart. Our study also observed increased expression of Jun family members in PDCMs after  
9 AMI, suggesting potential roles in cardiac adaptation and remodeling following injury. Further  
10 experiments are necessary to clarify the factors that stimulate AP-1 during cardiac remodeling upon  
11 PCSK9 deficiency.

12 Reducing LDL levels can mitigate cardiovascular risk, with statins, ezetimibe, and PCSK9 inhibitors  
13 playing pivotal roles in upregulating LDLR.<sup>40</sup> However, these drugs can paradoxically elevate plasma  
14 PCSK9 levels<sup>41,42</sup>, potentially leading to secondary risks. Additionally, reports noted that statin  
15 treatment alone can significantly reduce plasma VEGF concentrations<sup>43</sup> and suppress  
16 vasculogenesis.<sup>44</sup> In this study, both plasma VEGF-A and VEGF-C levels were unchanged in the  
17 plasma of patients with CAD using statins alone. Therefore, a second agent, such as ezetimibe or a  
18 PCSK9 inhibitor, is advised for patients at high cardiovascular risk or those intolerant to statins.  
19 Recent studies demonstrated that combining statins with PCSK9 inhibitors is more effective than  
20 combining statins with ezetimibe in reducing the risks of MI and stroke.<sup>45</sup> Our experiments suggested  
21 that adding PCSK9 antibody to statins in patients with CAD increases the number of reparative  
22 myeloid cells with PDCM-like properties and raises plasma VEGF-C levels, indicating a potentially  
23 favorable prognosis.

24 In conclusion, targeting myeloid-PCSK9 could lead to favorable therapeutic outcomes because of its  
25 cell type- and tissue-specific activities. Indeed, myeloid-PCSK9 deficiency in mice post-AMI and  
26 PCSK9 antibody-treated patients with CAD exhibited features of PDCMs promoting enhanced  
27 cardiac remodeling and disease alleviation. Our findings demonstrate, for the first time, a potential  
28 clinical strategy involving myeloid-specific PCSK9 for protecting against MI and other vascular  
29 diseases beyond lowering LDL-c.

30

## 1 **Affiliations**

2 Heart-Immune-Brain Network Research Center, Department of Life Sciences, Ewha Womans  
3 University, Seoul, 03760, Republic of Korea (S.H.M., N.H.Y., K.I.C., H.J., J.J., S-K.S., S.S., J.S.,  
4 H.Y.K., Y.S.N., G.T.O.), Department of Biological Sciences, Ulsan National Institute of Science &  
5 Technology (UNIST), Ulsan, 44919, South Korea (H.W.K., S.H.P.), Department of Vaccine  
6 Biotechnology, Andong National University, Andong, Republic of Korea (S.J.), Imvastech Inc., 52  
7 Ewhayeodae-gil, Seodaemun-gu, Seoul, 03760, Republic of Korea (S.S., G.T.O.), Korea Research  
8 Institute of Bioscience & Biotechnology, Laboratory Animal Resource Center, 30 Yeongudanji-ro,  
9 Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, 28116, Korea (W.K.Y.), Division of  
10 Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50-1, Seoul,  
11 03722, Republic of Korea (S-J.L., C.J.L.), Laboratory of Biochemical Neuroendocrinology, Montreal  
12 Clinical Research Institute (IRCM), Montreal, Quebec H2W 1R7, Canada (N.G.S.)

## 13 **Acknowledgements**

14 S.H.M., H.W.K., S.H.P., and G.T.O. designed the experiments. S.H.M. planned and performed most of  
15 the experiments, and help from N.H.Y., K.I.C., H.J., and Y.S.N. also contributed to several  
16 experiments. H.W.K. and S.H.P. conducted the scRNA-seq data analysis and validation. J.J., S.J., S-  
17 K.S., S.S., J.S., H.Y.K., N.H.Y., and H.J. advised and commented on the interpretation of the work.  
18 N.G.S. developed and provided *Pcsk9*<sup>-/-</sup>, *Pcsk9*<sup>fl/fl</sup> mice and discussed of the work. W.K.Y helped  
19 measure blood lipid levels. S-J.L. and C.J.L. contributed to the selected and recruited patient study  
20 participants. S.H.M. and G.T.O. wrote the manuscript (original draft), and S.H.M., H.W.K., S.H.P.,  
21 and G.T.O. reviewed and edited the manuscript. All authors read and approved the manuscript.

22 The apparatus including LSM780 and LSM880 NLO (Zeiss), LSRFortessa (Becton Dickinson), and  
23 FACSARIA Fusion (Becton Dickinson) at Ewha Fluorescence Core Imaging Center were utilized for  
24 major experiments.

## 25 **Sources of Funding**

26 This work was supported by a National Research Foundation of Korea (NRF) grant funded by the  
27 Korean government (NRF-2020R1A3B2079811 and RS-2023-00217798). The human study was  
28 financially supported by Imvastech Inc. (IRB of Severance Hospital; 4-2023-0509).

## 29 **Disclosures**


30 G.T.O. and S.S. are employed by Imvastech Inc. The remaining authors declare that the research was  
31 conducted in the absence of any commercial or financial relationships that could be construed as a  
32 potential conflict of interest.

## 1 References

- 2 1. Mezzaroma, E., *et al.* The inflammasome promotes adverse cardiac remodeling following acute  
3 myocardial infarction in the mouse. *Proc Natl Acad Sci U S A* **108**, 19725-19730 (2011).
- 4 2. Velagaleti, R.S., *et al.* Long-term trends in the incidence of heart failure after myocardial infarction.  
5 *Circulation* **118**, 2057-2062 (2008).
- 6 3. Seidah, N.G. & Prat, A. The Multifaceted Biology of PCSK9. *Endocr Rev* **43**, 558-582 (2022).
- 7 4. Jang, H.D., *et al.* Cyclase-associated protein 1 is a binding partner of proprotein convertase  
8 subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by  
9 proprotein convertase subtilisin/kexin type-9. *Eur Heart J* **41**, 239-252 (2020).
- 10 5. Reyes-Soffer, G., *et al.* Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in  
11 Healthy Humans. *Circulation* **135**, 352-362 (2017).
- 12 6. Ding, Z., Pothineni, N.V.K., Goel, A., Luscher, T.F. & Mehta, J.L. PCSK9 and inflammation: role of  
13 shear stress, pro-inflammatory cytokines, and LOX-1. *Cardiovasc Res* **116**, 908-915 (2020).
- 14 7. Ruscica, M., Tokgozoglul, L., Corsini, A. & Sirtori, C.R. PCSK9 inhibition and inflammation: A  
15 narrative review. *Atherosclerosis* **288**, 146-155 (2019).
- 16 8. de Couto, G. Macrophages in cardiac repair: Environmental cues and therapeutic strategies. *Exp Mol*  
17 *Med* **51**, 1-10 (2019).
- 18 9. Swirski, F.K. & Nahrendorf, M. Cardioimmunology: the immune system in cardiac homeostasis and  
19 disease. *Nat Rev Immunol* **18**, 733-744 (2018).
- 20 10. Andreadou, I., *et al.* PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid  
21 Metabolism and Inflammation. *Front Physiol* **11**, 602497 (2020).
- 22 11. Punch, E., Klein, J., Diaba-Nuhoho, P., Morawietz, H. & Garelnabi, M. Effects of PCSK9 Targeting:  
23 Alleviating Oxidation, Inflammation, and Atherosclerosis. *J Am Heart Assoc* **11**, e023328 (2022).
- 24 12. Laugsand, L.E., *et al.* Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in  
25 Norway. *JACC Basic Transl Sci* **1**, 568-575 (2016).
- 26 13. Almontashiri, N.A., *et al.* Plasma PCSK9 levels are elevated with acute myocardial infarction in two  
27 independent retrospective angiographic studies. *PLoS One* **9**, e106294 (2014).
- 28 14. Bao, X., *et al.* Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.  
29 *Signal Transduct Target Ther* **9**, 13 (2024).
- 30 15. Nishikido, T. & Ray, K.K. Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications  
31 for basic science and upcoming challenges. *Br J Pharmacol* **178**, 2168-2185 (2021).
- 32 16. Badimon, L., Luquero, A., Crespo, J., Pena, E. & Borrell-Pages, M. PCSK9 and LRP5 in macrophage  
33 lipid internalization and inflammation. *Cardiovasc Res* **117**, 2054-2068 (2021).
- 34 17. Marques, P., *et al.* Beneficial effects of PCSK9 inhibition with alirocumab in familial  
35 hypercholesterolemia involve modulation of new immune players. *Biomed Pharmacother* **145**, 112460  
36 (2022).
- 37 18. Guo, Y., *et al.* PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Triggers Vascular Smooth  
38 Muscle Cell Senescence and Apoptosis: Implication of Its Direct Role in Degenerative Vascular  
39 Disease. *Arterioscler Thromb Vasc Biol* **42**, 67-86 (2022).
- 40 19. Dadu, R.T. & Ballantyne, C.M. Lipid lowering with PCSK9 inhibitors. *Nat Rev Cardiol* **11**, 563-575  
41 (2014).
- 42 20. Tavori, H., Rashid, S. & Fazio, S. On the function and homeostasis of PCSK9: reciprocal interaction  
43 with LDLR and additional lipid effects. *Atherosclerosis* **238**, 264-270 (2015).
- 44 21. Ouimet, M., Barrett, T.J. & Fisher, E.A. HDL and Reverse Cholesterol Transport. *Circ Res* **124**, 1505-  
45 1518 (2019).
- 46 22. Pownall, H.J., Rosales, C., Gillard, B.K. & Gotto, A.M., Jr. High-density lipoproteins, reverse  
47 cholesterol transport and atherogenesis. *Nat Rev Cardiol* **18**, 712-723 (2021).
- 48 23. Kieu, T.Q., *et al.* Kinetics of LYVE-1-positive M2-like macrophages in developing and repairing dental  
49 pulp in vivo and their pro-angiogenic activity in vitro. *Sci Rep* **12**, 5176 (2022).
- 50 24. Revelo, X.S., *et al.* Cardiac Resident Macrophages Prevent Fibrosis and Stimulate Angiogenesis. *Circ*  
51 *Res* **129**, 1086-1101 (2021).
- 52 25. Lee, M., Lee, Y., Song, J., Lee, J. & Chang, S.Y. Tissue-specific Role of CX(3)CR1 Expressing  
53 Immune Cells and Their Relationships with Human Disease. *Immune Netw* **18**, e5 (2018).
- 54 26. Kubota, A. & Frangiannis, N.G. Macrophages in myocardial infarction. *Am J Physiol Cell Physiol*  
55 **323**, C1304-C1324 (2022).
- 56 27. Larsen, A.M.H., *et al.* Collagen Density Modulates the Immunosuppressive Functions of Macrophages.  
57 *J Immunol* **205**, 1461-1472 (2020).

- 1 28. Sapudom, J., *et al.* Collagen Fibril Density Modulates Macrophage Activation and Cellular Functions during Tissue Repair. *Bioengineering (Basel)* **7**(2020).
- 2 29. Bonder, C.S. & Ebert, L.M. Fos-icking for control of angiogenesis: increasing the longevity of peritoneal dialysis. *Kidney Int* **84**, 1065-1067 (2013).
- 3 30. Shiojima, I. & Walsh, K. Role of Akt signaling in vascular homeostasis and angiogenesis. *Circ Res* **90**, 1243-1250 (2002).
- 4 31. Weston, C.J., Zimmermann, H.W. & Adams, D.H. The Role of Myeloid-Derived Cells in the Progression of Liver Disease. *Front Immunol* **10**, 893 (2019).
- 5 32. Zhu, Y., *et al.* Hypoxia-primed monocytes/macrophages enhance postinfarction myocardial repair. *Theranostics* **12**, 307-323 (2022).
- 6 33. Russo, M.V., Latour, L.L. & McGavern, D.B. Distinct myeloid cell subsets promote meningeal remodeling and vascular repair after mild traumatic brain injury. *Nat Immunol* **19**, 442-452 (2018).
- 7 34. Shin, D., *et al.* PCSK9 stimulates Syk, PKCdelta, and NF-kappaB, leading to atherosclerosis progression independently of LDL receptor. *Nat Commun* **15**, 2789 (2024).
- 8 35. Florin, L., *et al.* Identification of novel AP-1 target genes in fibroblasts regulated during cutaneous wound healing. *Oncogene* **23**, 7005-7017 (2004).
- 9 36. Hartupee, J. & Mann, D.L. Neurohormonal activation in heart failure with reduced ejection fraction. *Nat Rev Cardiol* **14**, 30-38 (2017).
- 10 37. Hilfiker-Kleiner, D., *et al.* JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity. *Cardiovasc Res* **71**, 108-117 (2006).
- 11 38. Ye, N., Ding, Y., Wild, C., Shen, Q. & Zhou, J. Small molecule inhibitors targeting activator protein 1 (AP-1). *J Med Chem* **57**, 6930-6948 (2014).
- 12 39. Windak, R., *et al.* The AP-1 transcription factor c-Jun prevents stress-imposed maladaptive remodeling of the heart. *PLoS One* **8**, e73294 (2013).
- 13 40. Katzmann, J.L., Gouni-Berthold, I. & Laufs, U. PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects. *Front Physiol* **11**, 595819 (2020).
- 14 41. Dubuc, G., *et al.* A new method for measurement of total plasma PCSK9: clinical applications. *J Lipid Res* **51**, 140-149 (2010).
- 15 42. Sahebkar, A., Simental-Mendia, L.E., Guerrero-Romero, F., Golledge, J. & Watts, G.F. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. *Diabetes Obes Metab* **17**, 1042-1055 (2015).
- 16 43. Sahebkar, A., Ponziani, M.C., Goitre, I. & Bo, S. Does statin therapy reduce plasma VEGF levels in humans? A systematic review and meta-analysis of randomized controlled trials. *Metabolism* **64**, 1466-1476 (2015).
- 17 44. Urbich, C., Dernbach, E., Zeiher, A.M. & Dimmeler, S. Double-edged role of statins in angiogenesis signaling. *Circ Res* **90**, 737-744 (2002).
- 18 45. Khan, S.U., *et al.* PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. *BMJ* **377**, e069116 (2022).

39



**Figure 1. PCSK9 exacerbates myocardial injury by modulating cardiac macrophages in the ischemic heart.**


**A**, Experimental design: 10–12-week-old male *Pcsk9<sup>fl/fl</sup>* and *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* mice were subjected to LAD coronary artery ligation to induce AMI. Cardiac function was assessed using echocardiography and immune cell analysis by flow cytometry on day 3 or 7 post-surgery and then sacrificed. **B**, Mortality rates of male *Pcsk9<sup>fl/fl</sup>* and *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* mice up to 7 days post-surgery. **C**, Percent infarct size to the LV area (**Left**;  $n = 5$ ). LV wall thickness ( $\mu\text{m}$ ) post-LAD ligation in the MI-D7 groups of male *Pcsk9<sup>fl/fl</sup>* and *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* mice (**Right**;  $n = 5$ ). **D**, Echocardiographic assessment of ejection fraction (EF), LV end-systolic volume (LVESV), LV end-diastolic volume (LVEDV), stroke volume, and cardiac output. **E**, The counts of the indicated myeloid cells in the sham ( $n = 5$ ), MI-D3 ( $n = 4$ ), and MI-D7 ( $n \geq 4$ ) groups of *Pcsk9<sup>fl/fl</sup>* and *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* mice. **F**, Flow cytometry revealing BODIPY (493/503) staining of F4/80 macrophages from the sham ( $n = 3$ ) or MI-D3 ( $n = 5$ ) hearts of *Pcsk9<sup>+/+</sup>* and *Pcsk9<sup>-/-</sup>* mice, and from sham ( $n = 3$ ) or MI-D3 ( $n \geq 3$ ) hearts of *Pcsk9<sup>fl/fl</sup>* and *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* mice. For **C–F**, each dot represents one mouse. All data are presented as the mean  $\pm$  SEM. ns,  $P > 0.05$ ; \* $P < 0.05$ , \*\* $P < 0.01$ .



Characteristics	Sham			MI-D3			MI-D7		
	<i>Pcsk9<sup>fl/fl</sup></i>	<i>Lyz2<sup>cre</sup> Pcsk9<sup>fl/fl</sup></i>	<i>P</i>	<i>Pcsk9<sup>fl/fl</sup></i>	<i>Lyz2<sup>cre</sup> Pcsk9<sup>fl/fl</sup></i>	<i>P</i>	<i>Pcsk9<sup>fl/fl</sup></i>	<i>Lyz2<sup>cre</sup> Pcsk9<sup>fl/fl</sup></i>	<i>P</i>
Cholesterol (mg/dl)	92.83±5.53	79.0±5.11	0.1797	103.83±5.81	83.0±7.38	0.0823	87.17±5.47	92.0±5.26	0.6991
TG (mg/dl)	69.50±8.11	63.67±16.09	0.3939	45.16±5.52	44.0±8.00	0.7922	67.17±9.04	59.67±15.00	0.4848
HDL-c (mg/dl)	43.33±4.09	43.29±3.77	>0.9999	52.0±3.72	46.2±2.69	0.2677	48.0±3.26	52.43±4.47	0.2949
LDL-c (mg/dl)	6.17±0.65	5.85±0.59	0.6282	10.71±1.60	6.2±1.11	0.0732	6.60±1.16	6.17±1.28	0.7922
GOT (IU/L)	69.57±8.14	74.83±4.43	0.6282	163.5±24.69	160.8±37.10	>0.9999	74.83±11.33	70.67±9.09	>0.9999
GPT (IU/L)	42.38±5.39	31.22±4.56	0.0745	104.43±28.96	51.2±7.51	0.1061	35.71±4.73	36.0±2.93	0.5350
GLU (mg/dl)	262.88±15.24	240.89±23.87	0.6058	191.67±14.12	241.4±21.94	0.1775	217.57±18.35	250.86±7.96	0.1282
ALB (g/dl)	2.90±0.07	2.66±0.111	0.1388	3.09±0.15	2.86±0.09	0.2677	2.86±0.09	2.80±0.10	0.7104


**Table 1. Myeloid-specific PCSK9 deficiency does not affect plasma lipid levels after LAD ligation.**

Plasma lipid profiles were assessed in the sham ( $n = 6$ ), MI-D3 ( $n \geq 5$ ), and MI-D7 ( $n = 6$ ) groups of *Pcsk9<sup>fl/fl</sup>* and *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* mice. All data are presented as the mean  $\pm$  SEM. An unpaired two-tailed Student's *t*-test was used for statistical analysis. *P*-values are indicated for comparisons between *Pcsk9<sup>fl/fl</sup>* vs. *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* mice within each group. TG, Triglyceride; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; GLU, glucose; ALB, albumin. ns,  $P > 0.05$




**Figure 2. scRNA-seq analysis reveals PCSK9-dependent Cardiac Macrophages (PDCMs).**

**A**, Among the eight clusters (Figure IIIB), only macrophage-related clusters (Mo/Mac and Mo/Mac/DC) were subclustered, resulting in 11 newly defined subclusters. UMAP plots present these 11 subclusters and annotations of cells identified in ischemic hearts from the sham, MI-D3 *Pcsk9*<sup>+/+</sup>, and MI-D3 *Pcsk9*<sup>-/-</sup> groups. **B**, UMAP plots specifically highlighting PDCM clusters (Lyve1+ and Cx3cr1+MHCII+) and comparing their expression post-MI. **C**, Differential expression analysis of each cluster in the MI-D3 *Pcsk9*<sup>+/+</sup> group compared with the sham group (**Top**), and the MI-D3 *Pcsk9*<sup>-/-</sup> group compared with the MI-D3 *Pcsk9*<sup>+/+</sup> group (**Bottom**). **D**, Immunofluorescence (IF) staining of F4/80 (red) and Lyve1 (green) in AMI hearts. Scale bar, 20  $\mu$ m. **E**, Quantification and statistical analysis of the percentages of Lyve1<sup>+</sup> cells among F4/80<sup>+</sup> macrophages (**Left**;  $n \geq 4$ ). Quantification and statistical analysis of the numbers of Lyve1<sup>+</sup> macrophages (**Right**;  $n \geq 4$ ). **F**, IF staining of F4/80 (red) and CX<sub>3</sub>CR1 (green) in AMI hearts. Scale bar, 20  $\mu$ m. **G**, Quantification and statistical analysis of the percentages of CX<sub>3</sub>CR1<sup>+</sup> cells among F4/80<sup>+</sup> macrophages (**Left**;  $n \geq 4$ ). Quantification and statistical analysis of the numbers of CX<sub>3</sub>CR1<sup>+</sup> macrophages (**Right**;  $n \geq 4$ ). For **E** and **G**, each dot represents one mouse. All data are presented as the mean  $\pm$  SEM. \* $P < 0.05$ .




**Figure 3. PDCMs enhance cardiac remodeling during the healing phase.**

**A**, Scoring data present enriched reparative roles such as cardiac muscle cell development, cardiac muscle tissue development, and vasculogenesis in PDCMs (Lyve1+, Cx3cr1+MHCII+) compared with the findings in NPDCMs (Res Mf, Ccr2+, Isg Mf) in the ischemic heart. **B**, Immunofluorescence (IF) staining of the myofibroblast density in infarcts from *Pcsk9<sup>fl/fl</sup>* and *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* MI mice using  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA)<sup>+</sup> areas and quantitation graph at MI-D7. Scale bar, 20  $\mu$ m ( $n = 5$  per group). **C**, Masson's trichrome staining was used to label collagen in infarcted hearts from *Pcsk9<sup>fl/fl</sup>* and *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* MI mice and quantitation graph at MI-D7. Scale bar, 100  $\mu$ m (**Top**), 50  $\mu$ m (**Bottom**;  $n = 5$  per group). **D**, Immunofluorescence staining of the infarct microvascular density in *Pcsk9<sup>fl/fl</sup>* and *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* MI mice using CD31 and quantitation graph at MI-D7. Scale bar, 20  $\mu$ m ( $n = 5$  per group). **E**, qPCR analysis of the adhesion molecule *Pecam1* at MI-D3 ( $n \geq 3$ ) and MI-D7 ( $n = 5$ ) in AMI hearts. Data in **B–D**, are representative of three independent experiments. For **B–E**, each dot represents one mouse. All data are presented as the mean  $\pm$  SEM. ns,  $P > 0.05$ ; \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .




**Figure 4. Enrichment of AP-1-related genes in the PDCMs.**

**A**, Genes upregulated in the absence of PCSK9 were assessed by Enrich R pathway analysis for PDCMs. **B**, Violin plots presenting the expression of representative markers of AP-1 expression for NPDCMs (Res Mf, Ccr2<sup>+</sup>, Isg Mf, Ly6C low, Ly6C int, Ly6C high, cDC1, cDC2, Unknown) and PDCMs (Lyve1<sup>+</sup>, Cx3cr1+MHCII<sup>+</sup>) in the ischemic heart. **C**, Feature plots depicting single-cell gene expression of AP-1 family genes. **D**, Immunoblot analysis of sorted F4/80<sup>+</sup> cardiac macrophages for PDCMs from infarcted hearts on day 7. Data in **D**, are representative of three independent experiments. All data are presented as mean ± SEM. \*\*\*\**P* < 0.0001.



**Figure 5. PDCMs improve cardiac repair through VEGF-C activation.**

**A** and **B**, qPCR analysis of vascular endothelial growth factor (VEGF) family members, *Vegf-a* (**A**), *Vegf-c* (**B**) at MI-D3 ( $n \geq 3$ ) and MI-D7 ( $n = 5$ ) in AMI hearts. **C**, Immunoblot analysis of sorted F4/80<sup>+</sup> cardiac macrophages for VEGF-C from *Pcsk9<sup>fl/fl</sup>* and *Lyz2<sup>cre</sup>Pcsk9<sup>fl/fl</sup>* infarcted hearts on day 7. **D**, Secreted VEGF-C protein levels in supernatants from BMDM(IL-4/IL-13)s under ischemic conditions, assessed through ELISA ( $n = 4$ ). **E-F**, Sorted and cultured Mouse Cardiac Endothelial Cells (MCECs) from mouse hearts. Representative images of the Scratch assay at 0h and 24h after treatment with CoCl<sub>2</sub> and VEGF-C, respectively (**E**). Quantification and statistical analysis of the scratch wound area at 6, 12, and 24h compared to 0h (**F**). **G**, Immunoblot analysis for p-VEGFR2<sup>Y951</sup>, VEGFR2, p-Akt<sup>S473</sup>, and Akt expression and activation in MCECs after stimulation with CoCl<sub>2</sub> and VEGF-C, respectively ( $n = 4$ ). For **A,B,D,G**, each dot represents one mouse. Data in **E-G**, are representative of four independent experiments. All data are presented as mean  $\pm$  SEM. ns;  $P > 0.05$ ,  $*P < 0.05$ .



**Figure 6. PCSK9 inhibitors alter myeloid heterogeneity in the plasma of patients with CAD and human macrophages.** The study groups were as follows: **i)** non-CAD patients (hypertensive patients; Control group), **ii)** patients with CAD on statin therapy only, **iii)** patients with CAD on statin and PCSK9 antibody (Ab) therapy. PCSK9 Ab-treated patients with CAD were analyzed to explore changes in immune cell phenotypes. **A**, PCSK9 protein levels in plasma from each patient group as assessed by ELISA ( $n \geq 5$ ). **B**, Number of myeloid cells in each group analyzed by flow cytometry ( $n \geq 5$ ). **C**, VEGF-C protein levels in plasma from each patient group as assessed through ELISA ( $n \geq 7$ ). **D-F**, Immunoblot analysis of p-c-Jun<sup>S63</sup>, LDLR, HIF-1 $\alpha$ , and VEGF-C expression in THP-1(IL-4/IL-13) cells pretreated with alirocumab (a PCSK9 inhibitor) and SR11302 (an AP-1 inhibitor) (**D**). Quantitation of band density (**E-F**). **G**, Secreted VEGF-C protein levels in supernatants from THP-1(IL-4/IL-13)s pretreated with alirocumab and SR11302 under ischemic conditions as assessed through ELISA. For **A-C**, each dot represents one person. Data in **D-F**, are representative of three independent experiments. All data are presented as mean  $\pm$  SEM. ns;  $P > 0.05$ ,  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ ,  $****P < 0.0001$ .